Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Issue 4 (12th July 2017)

• Record Type: Journal Article
• Authors: Roberts, Kate; Culleton, Vanessa; Lwin, Zarnie; O'Byrne, Kenneth; Hughes, Brett GM
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 13:Issue 4(2017)
• Page Start: 277
• Page End: 288
• Publication Date: 2017-07-12
• Subjects: autoimmune -- CTLA4 -- immunotherapy -- PD1 -- PDL1; Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.12698
• Languages: English
• ISSNs: 1743-7555

Abstract

Abstract: Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a broad spectrum of malignancies. This new class of agents also challenges oncologists with a unique set of immune‐based toxicities. Early recognition and precise management of these toxicities can result in better outcomes, with minimization of toxicity and harm to the patient. This article provides a comprehensive review of immune‐based toxicities caused by immune checkpoint inhibitors, including recommendations for their investigation and guidelines for specific management.